Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2024 Earnings Conference Call March 27, 2025 4:30 AM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Conference Call Participants Operator Good afternoon, and welcome to our Fourth Quarter and Year End 2024 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode. We will open the call for questions-and-answers after our management's pr ...

Corporate Overview March 2025 NASDAQ: LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Employer ...

Exhibit 99.1 Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results www.lanternpharma.com Q4 & Year End 2024 Company Updates & Earnings Press Release. pp. 1 ● HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never- smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, position ...

Financial Data and Key Metrics Changes - The company recorded a net loss of approximately $4.5 million for Q3 2024, compared to a net loss of approximately $3.2 million for Q3 2023, representing an increase in loss per share from $0.29 to $0.42 [27] - R&D expenses increased to approximately $3.7 million in Q3 2024 from approximately $2.2 million in Q3 2023, driven by increased clinical trial activity [27] - General and administrative expenses rose slightly to approximately $1.5 million in Q3 2024 from approximately $1.3 million in Q3 2023, primarily due to higher professional and legal fees [28] - The cash position as of September 30, 2024, was approximately $28.1 million, expected to provide a runway into at least late 2025 [29] Business Line Data and Key Metrics Changes - The company has three precision oncology drug candidates advancing through clinical trials, all guided by the RADR AI platform, with significant clinical progress reported [11][10] - The Harmonic trial for LP-300 showed an 86% clinical benefit rate in the first seven patients, indicating promising early data [12] - LP-184 and LP-284 are in Phase Ia trials, with over 50 patients dosed and no dose-limiting toxicities observed [15] Market Data and Key Metrics Changes - The expansion of the MARTA trial into Asia, specifically Japan and Taiwan, is strategically important due to the higher prevalence of never smoker lung cancer in these regions [13] - The market opportunity for LP-284 in the US and Europe is estimated to exceed $2.8 billion to $3 billion annually, targeting 16,000 to 20,000 new patients [48] Company Strategy and Development Direction - The company is focused on leveraging AI and machine learning to transform oncology drug development, aiming to reduce costs and timelines while advancing precision therapies [10][11] - The establishment of Starlight Therapeutics aims to focus on CNS and brain cancer indications, with plans for Phase Ib and II trials expected to launch in early 2025 [35][86] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of AI in drug development, stating that the industry is undergoing a fundamental transformation [7] - The FDA's Fast Track designation for LP-184 in glioblastoma is seen as a significant milestone, potentially expediting development and increasing commercial value [37] - The company is optimistic about the future, expecting several clinical readouts and milestones in the upcoming quarters [76] Other Important Information - The company received three new FDA rare pediatric designations for LP-184, which could lead to priority review vouchers upon FDA approval [21] - The RADR AI platform has guided the development of three AI-guided drug candidates into ongoing clinical trials, showcasing the platform's effectiveness [32] Q&A Session Summary Question: When do we expect additional data regarding our HARMONIC and LP-300 trial? - The company expects to gather more data after enrolling 14 to 28 additional patients and plans an interim analysis at 31 patients, with results anticipated around mid-next year [79] Question: Any updates on how Radar is growing and collaboration efforts? - The collaboration with Oregon Therapeutics is progressing well, with expectations to finalize the first phase by the end of the year, and the company is looking at additional collaborations with larger biotech firms [80][81] Question: Can we speak to any partnership interest? - Discussions are ongoing with larger pharma companies in Japan regarding potential partnerships, particularly due to the high prevalence of non-small cell lung cancer among never smokers in East Asia [82] Question: Updates on Starlight Therapeutics and the Scientific Advisory Board members? - The company is excited about the involvement of prominent experts in the Scientific Advisory Board, which is expected to enhance the potential of their CNS cancer programs [85][86]

Financial Performance - The company reported net losses of approximately $14.91 million for the nine months ended September 30, 2024, compared to $11.78 million for the same period in 2023, reflecting an increase in operating expenses [91]. - The total operating expenses for the nine months ended September 30, 2024, were approximately $16.32 million, compared to $13.00 million for the same period in 2023 [97]. - The company expects to continue incurring significant operating losses for several years as it advances clinical trials and seeks regulatory approvals for drug candidates [108]. - Net cash used in operating activities was approximately $13,841,000 for the nine months ended September 30, 2024, compared to $10,961,000 for the nine months ended September 30, 2023 [105]. - Interest income increased by approximately $83,000 from $498,000 for the nine months ended September 30, 2023, to $581,000 for the nine months ended September 30, 2024 [104]. Research and Development - Research and development expenses totaled approximately $11.86 million for the nine months ended September 30, 2024, up from $8.32 million in the same period of 2023, indicating a significant investment in drug development [94]. - Research and development expenses increased by approximately $3,535,000, or 42%, from $8,321,000 for the nine months ended September 30, 2023, to $11,856,000 for the nine months ended September 30, 2024 [103]. - Research and development expenses increased by approximately $1,507,000, or 68%, from $2,210,000 for the three months ended September 30, 2023, to $3,717,000 for the three months ended September 30, 2024 [99]. - The company has three lead drug candidates (LP-300, LP-184, and LP-284) currently in clinical phases, with LP-300 undergoing a targeted Phase 2 trial for advanced non-small cell lung cancer [86]. - The company formed a wholly-owned subsidiary, Starlight Therapeutics, in January 2023 to focus on CNS and brain cancer drug development, particularly for LP-184 [85]. - The ADC program is advancing with a research collaboration with Bielefeld University, focusing on developing ADCs utilizing cryptophycin, which has shown promising antitumor activity [87]. Funding and Capital - The company has not generated any revenue to date and has financed operations primarily through equity sales [91]. - The company anticipates needing substantial additional funding to complete clinical trials, which may dilute existing stockholders' ownership interests [110]. - The company raised capital historically through the issuance of equity securities [113]. Assets and Liquidity - As of September 30, 2024, total assets were approximately $30.3 million, with liquidity including approximately $28.1 million of cash, cash equivalents, and marketable securities [108]. - The company maintains significant cash and cash equivalents exceeding federally insured limits, with most balances above $250,000 guaranteed by the FDIC [113]. Currency and Inflation - Foreign currency gains were approximately $28,000 for the nine months ended September 30, 2024, compared to losses of approximately $130,000 for the nine months ended September 30, 2023 [114]. - The company does not expect the impact of foreign currency losses to be material in future periods [114]. - Inflation has not materially affected the company's results of operations during the reported periods, but it could have a greater impact in the future if current levels persist [115]. Internal Controls - The company's disclosure controls and procedures were evaluated as effective as of September 30, 2024 [118]. - There were no changes in internal control over financial reporting that materially affected the company during the three months ended September 30, 2024 [119]. - The company recognizes that inherent limitations in control systems may lead to undetected errors or fraud [120]. - The company does not participate in foreign currency hedging activities and does not have derivative financial instruments [114].

Clinical Trials and Drug Development - Lantern Pharma is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials[1]. - The Phase 2 LP-300 Harmonic™ Trial showed an 86% clinical benefit rate in the initial 7 patient cohort, with a 43% objective response rate and an average tumor size reduction of 51% in partial responders[2][10]. - LP-184 received Fast Track Designation from the FDA for glioblastoma, with plans for a Phase 1b/2 clinical trial targeted to begin in early 2025[3][14]. - The Harmonic™ trial is expanding to Japan and Taiwan, targeting a potential global market estimated at over $4 billion annually for never-smoker NSCLC[12]. - LP-284 is in Phase 1a clinical trials with no dose-limiting toxicities observed, targeting an estimated annual market potential of over $3 billion for MCL, DHL, and HGBL[16]. - Lantern's AI-driven pipeline is estimated to have a combined annual market potential of over $15 billion across multiple cancer indications[26]. - Lantern Pharma has not yet received FDA marketing approval for any of its product candidates, which poses a risk to future revenue generation[27]. - The company is actively seeking partnerships and collaborations to support its drug development efforts and maximize commercial potential[27]. - Lantern Pharma's strategic plans include advancing its antibody drug conjugate (ADC) development program, with specific timelines for clinical trials and patient enrollment yet to be established[27]. - Lantern Pharma's research and development efforts are aimed at streamlining the drug development process, but funding risks remain a concern for future clinical trials[27]. Financial Performance - As of September 30, 2024, Lantern Pharma reported approximately $28.1 million in cash, cash equivalents, and marketable securities, down from $41.3 million at the end of 2023[6][17]. - Research and development expenses for Q3 2024 were approximately $3.7 million, compared to $2.2 million in Q3 2023[18]. - The net loss for Q3 2024 was approximately $4.5 million, or $0.42 per share, compared to a net loss of approximately $3.2 million, or $0.29 per share, in Q3 2023[19]. Strategic Focus and Innovation - The company is focusing on building an efficient internal clinical operations team to manage ongoing clinical trial costs more effectively[21]. - Lantern Pharma's Q3 2024 earnings report highlights a significant focus on advancing its RADR platform for drug candidate identification and patient population targeting[27]. - The company emphasizes its commitment to leveraging artificial intelligence and machine learning to enhance oncology drug discovery and development processes[27]. - The company acknowledges potential market sizes and patient populations for its drug candidates, although specific estimates were not disclosed[27]. - The company has outlined its intention to provide regular updates through various channels, including its website and SEC filings, to ensure broad dissemination of material information[28]. - Lantern Pharma's forward-looking statements indicate a cautious approach to future performance, highlighting the uncertainties inherent in drug development[27]. - The company has a clear focus on transforming the pace, risk, and cost of oncology drug discovery through innovative technologies[27].

Second Quarter 2024 Operating & Financial Results Conference Call / Webinar NASDAQ :LTRN With additional focus on preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic Trial August 8th, 2024 4:30 PM Eastern Time Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other ...

Lantern Pharma Inc. (NASDAQ:LTRN) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Dr. Reggie Ewesuedo - Vice President, Clinical Development Conference Call Participants John Vandermosten - Zacks Research Operator Good afternoon. And welcome to our Second Quarter 2024 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode. We will open the call for question ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------|----------------------------------------- ...